Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14536672 | 0.78 | — | — | |
| SCHEMBL4382702 | 0.77 | CES2 (0.35) | CES2CES1TOP2ATOP2B | |
| SCHEMBL13893272 | 0.77 | CES2 (0.35) | CES2CES1TOP2ATOP2B | |
| SCHEMBL16156952 | 0.75 | ALDH1A1 (0.37) | CES2CES1ALDH1A1LMNAGSK3B | |
| SCHEMBL16154390 | 0.75 | GSK3B (0.37) | CES2CES1ALDH1A1LMNAGSK3B | |
| SCHEMBL9967707 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL14895473 | 0.73 | ALDH1A1 (0.36) | CES2CES1ALDH1A1LMNAGSK3B | |
| SCHEMBL25414922 | 0.71 | — | — | |
| SCHEMBL1239348 | 0.71 | — | — | |
| SCHEMBL24105124 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560451-B2 | 2-Oxo,3-methyl,4-imino,6-((3-cyanophenyl)thien-2-yl)-perhydro-1,3,5-oxadiazaepine; cardiovascular disorders; HIV, plasmepins, cathepsin D and protozoal enzyme inhibitors; treating cognitive and ineurodegenerative diseases in combination with a cholinesterase inhibitor or a muscarinic antagonist | SCHERING CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560451-B2 | 2-Oxo,3-methyl,4-imino,6-((3-cyanophenyl)thien-2-yl)-perhydro-1,3,5-oxadiazaepine; cardiovascular disorders; HIV, plasmepins, cathepsin D and protozoal enzyme inhibitors; treating cognitive and ineurodegenerative diseases in combination with a cholinesterase inhibitor or a muscarinic antagonist | SCHERING CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070099875-A1 | Aspartyl protease inhibitors | SCHERING CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070099875-A1 | Aspartyl protease inhibitors | SCHERING CORPORATION | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099875-A1 | Aspartyl protease inhibitors | PRSS1, PRSS3, TMPRSS11D | CES2 439/4885CES1 114/4885ALDH1A1 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.